Array Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.17), $0.06 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $42.2 million versus the consensus estimate of $26.67 million.

For earnings history and earnings-related data on Array Biopharma (ARRY) click here.